Iterum Therapeutics plc 8-K

What Happened
Iterum Therapeutics plc announced it received a delisting determination letter from The Nasdaq Stock Market LLC on February 24, 2026. Nasdaq found the company noncompliant with Listing Rule 5550(a)(2) (minimum bid price $1.00) and scheduled suspension of trading and delisting effective at the open of business on March 5, 2026 unless Iterum requests a hearing before an independent Nasdaq Hearings Panel. Nasdaq also indicated it intends to file Form 25‑NSE with the SEC after applicable appeal periods to complete the delisting.

Key Details

• Nasdaq cited noncompliance with the Bid Price Rule (Nasdaq Listing Rule 5550(a)(2): minimum $1.00 per share).
• Suspension of trading and delisting scheduled effective March 5, 2026 unless the company requests a hearing.
• Iterum remains noncompliant with Nasdaq Listing Rule 5550(b)(2) (minimum market value of listed securities of $35.0 million); the company had a prior compliance period through June 9, 2026 to try to regain that standard.
• The company is evaluating strategic alternatives (including possible wind‑down, bankruptcy, liquidation) and may file Form 15 to suspend SEC reporting if delisted; there is no assurance an appeal would succeed.

Why It Matters
This filing signals a significant risk to shareholders: potential suspension and delisting from Nasdaq would reduce liquidity and could shift the shares to less-regulated OTC markets. Iterum’s disclosure that it may pursue a wind‑down or a bankruptcy/liquidation process indicates that equity holders could be unlikely to receive meaningful distributions. The company’s limited ability to raise capital and the possibility of suspending SEC reporting (Form 15) would further reduce available public information, increasing uncertainty for investors.